Infant Bacterial Therapeutics AB (publ) announced that at the AGM held on May 15, 2018, approved the election of Lilian Henningson Wikström and Kristina Sjöblom Nygren as new board members. Since 2010 Lilian Henningson Wikström has been CEO of Karolinska Institutet Innovations AB in Solna. Lilian Henningson Wikström is judged to be independent both in relation to major shareholders and to the company and company management. Kristina Sjöblom Nygren has been Chief Medical Officer, Head of Development, since 2018 at Santhera Pharmaceuticals in Basel, Switzerland. Kristina Sjöblom Nygren has extensive experience from the pharmaceutical industry, where she has held among other positions Head of Clinical Development at SOBI. Kristina Sjöblom Nygren is considered to be independent both in relation to major shareholders and to the company and company management.